鹿特丹研究中糖尿病药物与开角型青光眼、年龄相关性黄斑变性和白内障的关联
该前瞻性人群队列研究纳入鹿特丹研究3个独立队列的11260名参与者,评估2型糖尿病及二甲双胍、胰岛素、磺脲类衍生物与开角型青光眼、年龄相关性黄斑变性、白内障的关联及终生累积风险。未治疗的2型糖尿病与三种眼病风险升高相关,二甲双胍与开角型青光眼风险降低相关,其他糖尿病药物与年龄相关性黄斑变性风险降低相关。
要点
- 未治疗的2型糖尿病与开角型青光眼、年龄相关性黄斑变性和白内障风险升高相关。
- 二甲双胍治疗与开角型青光眼风险降低相关,其他糖尿病药物与年龄相关性黄斑变性风险降低相关。
- 二甲双胍使用者开角型青光眼终生累积风险低于无2型糖尿病者,其他糖尿病药物使用者年龄相关性黄斑变性终生累积风险低于无2型糖尿病者。
核心结论
- 该队列研究结果提示,糖尿病与白内障明确相关,但糖尿病药物与白内障不相关。
- 二甲双胍治疗与开角型青光眼风险降低相关,其他糖尿病药物与年龄相关性黄斑变性风险降低相关。
- 获益证明需要干预性临床试验。
研究设计与样本
- 该队列研究纳入鹿特丹研究(前瞻性人群队列)3个独立队列的参与者,时间范围为1990年4月23日至2014年6月25日。
- 共纳入11260名参与者,平均(标准差)年龄65.1(9.8)岁,女性6610名(58.7%)。
- 参与者接受 incident 眼病(开角型青光眼、年龄相关性黄斑变性、白内障)监测,并有基线血清葡萄糖测量。
- 收集了糖尿病药物使用数据和眼科检查数据。
主要发现
- 2406名参与者(28.4%)诊断为2型糖尿病;7394名参与者中324名(4.4%)诊断开角型青光眼;10993名参与者中1935名(17.6%)诊断年龄相关性黄斑变性;11260名参与者中4203名(37.3%)诊断白内障。
- 未治疗的2型糖尿病与开角型青光眼风险升高相关(OR 1.50;95%CI 1.06-2.13;P=0.02),与年龄相关性黄斑变性风险升高相关(OR 1.35;95%CI 1.11-1.64;P=0.003),与白内障风险升高相关(OR 1.63;95%CI 1.39-1.92;P<0.001)。
- 二甲双胍治疗的2型糖尿病与开角型青光眼风险降低相关(OR 0.18;95%CI 0.08-0.41;P<0.001)。
- 其他糖尿病药物(即胰岛素、磺脲类衍生物)与年龄相关性黄斑变性风险降低相关(合并OR 0.32;95%CI 0.18-0.55;P<0.001)。
- 开角型青光眼终生累积风险:二甲双胍使用者为1.5%(95%CI 0.01%-3.1%),低于无2型糖尿病者的7.2%(95%CI 5.7%-8.7%);年龄相关性黄斑变性终生累积风险:其他糖尿病药物使用者为17.0%(95%CI 5.8%-26.8%),低于无2型糖尿病者的33.1%(95%CI 30.6%-35.6%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Recent studies suggest that the diabetes drug metformin has a protective effect on open-angle glaucoma (OAG) and age-related macular degeneration (AMD). However, studies have not addressed the critical issue of confounding by indication, and associations have not been evaluated in a large prospective cohort. OBJECTIVE: To determine the association between diabetes medication and the common eye diseases OAG, AMD, and cataract and to evaluate their cumulative lifetime risks in a large cohort study. DESIGN, SETTING, AND PARTICIPANTS: This cohort study included participants from 3 independent cohorts from the prospective, population-based Rotterdam Study between April 23, 1990, and June 25, 2014. Participants were monitored for incident eye diseases (OAG, AMD, cataract) and had baseline measurements of serum glucose. Data on diabetes medication use and data from ophthalmologic examinations were gathered. EXPOSURES: Type 2 diabetes (T2D) and the diabetes medications metformin, insulin, and sulfonylurea derivatives. MAIN OUTCOMES AND MEASURES: Diagnosis and cumulative lifetime risk of OAG, AMD, and cataract. RESULTS: This study included 11 260 participants (mean [SD] age, 65.1 [9.8]; 6610 women [58.7%]). T2D was diagnosed in 2406 participants (28.4%), OAG was diagnosed in 324 of 7394 participants (4.4%), AMD was diagnosed in 1935 of 10 993 participants (17.6%), and cataract was diagnosed in 4203 of 11 260 participants (37.3%). Untreated T2D was associated with a higher risk of OAG (odds ratio [OR], 1.50; 95% CI, 1.06-2.13; P = .02), AMD (OR, 1.35; 95% CI, 1.11-1.64; P = .003), and cataract (OR, 1.63; 95% CI, 1.39-1.92; P < .001). T2D treated with metformin was associated with a lower risk of OAG (OR, 0.18; 95% CI, 0.08-0.41; P < .001). Other diabetes medication (ie, insulin, sulfonylurea derivates) was associated with a lower risk of AMD (combined OR, 0.32; 95% CI, 0.18 to 0.55; P < .001). The cumulative lifetime risk of OAG was lower for individuals taking metformin (1.5%; 95% CI, 0.01%-3.1%) than for individuals without T2D (7.2%; 95% CI, 5.7%-8.7%); the lifetime risk of AMD was lower for individuals taking other diabetes medication (17.0%; 95% CI, 5.8%-26.8% vs 33.1%; 95% CI, 30.6%-35.6%). CONCLUSIONS AND RELEVANCE: Results of this cohort study suggest that, although diabetes was clearly associated with cataract, diabetes medication was not. Treatment with metformin was associated with a lower risk of OAG, and other diabetes medication was associated with a lower risk of AMD. Proof of benefit would require interventional clinical trials.
引用
- Vergroesen JE, Thee EF, Ahmadizar F, et al. Association of Diabetes Medication With Open-Angle Glaucoma, Age-Related Macular Degeneration, and Cataract in the Rotterdam Study. JAMA Ophthalmol. 2022. PMID: 35587864. doi:10.1001/jamaophthalmol.2022.1435
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。